SAINT LAURENT, Quebec, Aug. 04, 2022 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (“IntelGenx”), a leader in pharmaceutical films,...
CAMBRIDGE, Mass., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives...
ISELIN, N.J., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial biopharmaceutical company working to develop...
Madrigal remains on track to announce topline data from the Phase 3 MAESTRO-NASH biopsy study in the fourth quarterCONSHOHOCKEN, Pa.,...
TUCSON, Ariz., Aug. 04, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing...
– CFT7455, a Novel IKZF1/3 Degrader, Advancing Through Dose Escalation Portion of Phase 1/2 Clinical Trial – – Phase 1/2 Clinical...
Study evaluating the safety and efficacy of gemlapodect (NOE-105) in adults with Childhood Onset Fluency Disorder (also known as stuttering)Top-line...
Odyssey Health, Inc. Launches New Corporate Website $ODYY - Odyssey Health, Inc. - New Corporate WebsiteLas Vegas, NV, Aug. 04,...
COPENHAGEN, Denmark, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) announced today that the company will hold...
ROCKVILLE, Md., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics...
– MGTA-117 Phase 1/2 clinical trial progress continues and remains consistent with earlier observations of target binding, target cell reductions,...
Safety evaluation of 43 patients with no grade 3 or higher treatment-related adverse eventsFLORHAM PARK, N.J., Aug. 04, 2022 (GLOBE...
SAN DIEGO, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that Peter J. Trainer, M.D.,...
A total of 654 adults and children, age six and older, have been enrolled in the INTEGUMENT-1 trialEnrollment continues in...
Management to host conference call and webcast on August 15th at 5:00 pm EDT / 2:00 pm PDTSAN DIEGO, Aug....
The combination of data and analytics will accelerate pharmaceutical breakthroughs by helping clinical trial teams uncover the best sites and...
Single ascending dose (SAD) Phase 1 Study completed in Australia with a maximum dose of 2,000 mg.Pharmacokinetics (PK) were dose...
BOSTON, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights...
SAN DIEGO, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutics,...
Scalable, high-resolution, sample-specific analysis brings genomics and proteomics together to enable novel biological insights with the click of a buttonREDWOOD...